Lipid-Based Anticancer Prodrugs

Part of the Macromolecular Anticancer Therapeutics book series (CDD&D)


Lipids are biomolecules constituting the principal components of the living cells. Chemical association of drug molecules with lipids may alter their in vivo pharmacokinetics/pharmacodynamics and even, in certain cases, their toxicity profile. Successful design of a lipid–anticancer prodrug highly depends on the lipid’s carbon chain length, on the configuration of the double bonds, and on the location and nature of the covalent linkage with the drug. In general, well–designed lipid–anticancer prodrugs display better cellular penetration, controlled drug release property, better pharmacokinetics, improved tumor accumulation, and better cellular penetration leading to enhanced therapeutic activity and lower toxicity. Thus, the better therapeutic index results from a controlled exposure of the conjugated drug to the biological environment. Noteworthy, in the treatment of cancers, drug resistance is one of the most important clinical concerns. Thus, there is a real need to develop new chemical entities able to bypass the resistance factors, thus displaying an improved therapeutic response. In this context, lipid prodrugs of anticancer agents are important actors in overcoming the resistance to cancers, at least at the preclinical stage. This chapter aims to discuss in detail about the various lipids employed in anticancer drug delivery applications. The current stage of their development either preclinical or clinical is also presented.


Valproic Acid Conjugate Linoleic Acid Anticancer Activity Conjugate Linoleic Acid Isomer Elaidic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



ATP-binding cassette


Adenine nucleotide translocator


1-β-d-Arabinofuranosylcytosine, cytarabine


1-β-d-Arabinofuranosylcytosine triphosphate


Adenosine triphosphate


Butyric acid


Cholesterol–polyethyleneglycol 2000


Conjugated linoleic acid


deoxycytidine kinase




Docosahexaenoic acid


Deoxyribonucleic acid


Essential fatty acid


Eicosapentaenoic acid


Gemcitabine monophosphate


gemcitabine triphosphate


Human epidermal growth factor receptor-2




Low-density lipoprotein


Multidrug resistant


Mitomycin C


Maximal tolerable dose




Nicotinamide adenine dinucleotide


Non-small cell lung cancer


Protein tyrosine kinase


Polyunsaturated fatty acid


Rat natural killer-16


Squalenoyl gemcitabine




  1. 1.
    Fahy E, Subramaniam S, Brown HA et al. (2005) A comprehensive classification system for lipids. J Lipid Res 46:839–861PubMedGoogle Scholar
  2. 2.
    Chicco AJ, Sparagna GC (2007) Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 292:C33–C44PubMedGoogle Scholar
  3. 3.
    Noel H, Pande SV (1986) An essential requirement of cardiolipin for mitochondrial carnitine acylcarnitine translocase activity. Lipid requirement of carnitine acylcarnitine translocase. Eur J Biochem 155:99–102PubMedGoogle Scholar
  4. 4.
    Hoffmann B, Stockl A, Schlame M et al. (1994) The reconstituted ADP/ATP carrier activity has an absolute requirement for cardiolipin as shown in cysteine mutants. J Biol Chem 269:1940–1944PubMedGoogle Scholar
  5. 5.
    Fry M, Green DE (1981) Cardiolipin requirement for electron transfer in complex I and III of the mitochondrial respiratory chain. J Biol Chem 256:1874–1880PubMedGoogle Scholar
  6. 6.
    Eble KS, Coleman WB, Hantgan RR et al. (1990) Tightly associated cardiolipin in the bovine heart mitochondrial ATP synthase as analyzed by 31P nuclear magnetic resonance spectroscopy. J Biol Chem 265:19434–19440PubMedGoogle Scholar
  7. 7.
    Gonzalvez F, Gottlieb E (2007) Cardiolipin: Setting the beat of apoptosis. Apoptosis 12:877–885PubMedGoogle Scholar
  8. 8.
    Liu J, Weiss A, Durrant D et al. (2004) The cardiolipin-binding domain of Bid affects mitochondrial respiration and enhances cytochrome c release. Apoptosis 9:533–541PubMedGoogle Scholar
  9. 9.
    Marchesini N, Hannun YA (2004) Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82:27–44PubMedGoogle Scholar
  10. 10.
    Mimeault M (2002) New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer. FEBS Lett 530:9–16PubMedGoogle Scholar
  11. 11.
    Cai Z, Bettaieb A, El Mahdani N et al. (1997) Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem 272:6918–6926PubMedGoogle Scholar
  12. 12.
    Sawai H, Okazaki T, Takeda Y et al. (1997) Ceramide-induced translocation of protein kinase C-delta and -epsilon to the cytosol. Implications in apoptosis. J Biol Chem 272:2452–2458PubMedGoogle Scholar
  13. 13.
    Tepper AD, de Vries E, Van Blitterswijk WJ et al. (1999) Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J Clin Invest 103:971–978PubMedGoogle Scholar
  14. 14.
    Gulbins E, Kolesnick R (2003) Raft ceramide in molecular medicine. Oncogene 22:7070–7077PubMedGoogle Scholar
  15. 15.
    Schenck M, Carpinteiro A, Grassmé H et al. (2007) Ceramide: physiological and pathophysiological aspects. Arch Biochem Biophys 462:171–175PubMedGoogle Scholar
  16. 16.
    Zhang Y, Mattjus P, Schmid PC et al. (2001) Involvement of the acid sphingomyelinase pathway in uva-induced apoptosis. J Biol Chem 276:11775–11782PubMedGoogle Scholar
  17. 17.
    Paris F, Fuks Z, Kang A et al. (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293–297PubMedGoogle Scholar
  18. 18.
    Matsumoto A, Comatas KE, Liu L et al. (2003) Screening for nitric oxide-dependent protein-protein interactions. Science 301:657–661PubMedGoogle Scholar
  19. 19.
    Das UN (2006) Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 1:420–439PubMedGoogle Scholar
  20. 20.
    Sauer LA, Nagel WO, Dauchy RT et al. (1986) Stimulation of tumor growth in adult rats in vivo during an acute fast. Cancer Res 46:3469–3475PubMedGoogle Scholar
  21. 21.
    Sauer LA, Dauchy RT (1990) Tumour-host metabolic interrelationships. Biochem Soc Trans 18:80–82.PubMedGoogle Scholar
  22. 22.
    Sauer LA, Dauchy RT (1992) The effect of ω-6 and ω-3 fatty acids on 3H-thymidine incorporation in hepatoma 7288CTC perfused in situ. Brit J Cancer 66:297–303PubMedGoogle Scholar
  23. 23.
    James M, Gibson R, Cleland L (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nut 71:343S–348SGoogle Scholar
  24. 24.
    Colomer R, Moreno-Nogueira JM, García-Luna PP et al. (2007) n-3 Fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97:823–831PubMedGoogle Scholar
  25. 25.
    Ip C (1997) Review of the effects of trans fatty acids, oleic acid, n–3 polyunsaturated fatty acids, and conjugated linoleic acid on mammary carcinogenesis in animals. Am J Clin Nutr 66:1523S–1529SPubMedGoogle Scholar
  26. 26.
    Rose DP, Connolly JM (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83:217–244PubMedGoogle Scholar
  27. 27.
    Terry PD, Rohan TE, Wolk A (2003) Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. Am J Clin Nutr 77:532–543PubMedGoogle Scholar
  28. 28.
    Osborne MP, Herschcopf RJ, Bradlow HL et al. (1988) Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. Cancer Invest 6:629–632Google Scholar
  29. 29.
    Nagata C, Takatsuka N, Kawakami N et al. (2000) Relationships between types of fat consumed and serum estrogen and androgen concentrations in Japanese men. Nutr Cancer 38:163–167PubMedGoogle Scholar
  30. 30.
    Heird WC, Lapillonne A (2005) The role of essential fatty acids in development. Annu Rev Nutr 25:549–571PubMedGoogle Scholar
  31. 31.
    Stillwell W, Shaikh SA, Zerouga M et al. (2005). Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 45:559–579PubMedGoogle Scholar
  32. 32.
    Giorgione J, Epand RM, Buda C et al. (1995) Role of phospholipids containing docosahexaenoyl chains in modulating the activity of protein kinase C. Proc Natl Acad Sci USA 92:9767–9770PubMedGoogle Scholar
  33. 33.
    Jenski LJ, Nanda PK, Jiricko P et al. (2000). Docosahexaenoic-containing phosphatidylcholine affects the binding of monoclonal antibodies to purified Kb reconstituted into liposomes. Biochim Biophys Acta 1467:293–306PubMedGoogle Scholar
  34. 34.
    Siddiqui RA, Jenski LJ, Neff K et al. (2001) Docosahexaenoic acid induces apoptosis in Jurcat cells by a protein phosphate-mediated pathway. Biochim Biophys Acta 1499: 265–275PubMedGoogle Scholar
  35. 35.
    Connolly JM, Gilhooly EM, Rose DP (1999) Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDAMB-231 breast cancer cell growth and apoptosis in nude mice. Nutr Cancer 35:44–49PubMedGoogle Scholar
  36. 36.
    Siddiqui RA, Shaikh SR, Sech LA et al. (2004) Omega-3 fatty acids: health benefits and cellular mechanisms of action. Mini-Rev Med Chem 4:859–871PubMedGoogle Scholar
  37. 37.
    Kelly GS (2001) Conjugated linoleic acid: a review. Altern Med Rev 6:367–382PubMedGoogle Scholar
  38. 38.
    Bhattacharya A, Banu A, Rahman M et al. (2006) Biological effects of conjugated linoleic acids in health and disease. J Nutr Biochem 17:789–810PubMedGoogle Scholar
  39. 39.
    Griinari JM, Corl BA, Lacy SH et al. (2000) Conjugated linoleic acid is synthesized endogenously in lactating dairy cows by Delta(9)-desaturase. J Nutr 130:2285–2291PubMedGoogle Scholar
  40. 40.
    Thomas Yeung CH, Yang L, Huang Y et al. (2000) Dietary conjugated linoleic acid mixture affects the activity of intestinal acyl coenzyme A: cholesterol acyltransferase in hamsters. Br J Nutr 84:935–941PubMedGoogle Scholar
  41. 41.
    Igarashi M, Miyazawa T (2001) The growth inhibitory effect of conjugated linoleic acid on a human hepatoma cell line, HepG2, is induced by a change in fatty acid metabolism, but not the facilitation of lipid peroxidation in the cells. Biochim Biophys Acta 1530:162–171PubMedGoogle Scholar
  42. 42.
    Schonberg S, Krokan HE (1995) The inhibitory effect of conjugated dienoic derivatives (CLA) of linoleic acid on the growth of human tumor cell lines is in part due to increased lipid peroxidation. Anticancer Res 15:1241–1246PubMedGoogle Scholar
  43. 43.
    Cesano A, Visonneau S, Scimeca JA et al. (1998) Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. Anticancer Res 18:1429–1434PubMedGoogle Scholar
  44. 44.
    Liew C, Schut HA, Chin SF et al. (1995) Protection of conjugated linoleic acids against 2-amino-3- methylimidazo [4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. Carcinogenesis 16:3037–3043PubMedGoogle Scholar
  45. 45.
    Chen BQ, Xue YB, Liu JR et al. (2003) Inhibition of conjugated linoleic acid on mouse fore stomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms. World J Gastroenterol 9:44–49PubMedGoogle Scholar
  46. 46.
    Kuniyasu H, Yoshida K, Sasaki T et al. (2006) Conjugated linoleic acid inhibits peritoneal metastasis in human gastrointestinal cancer cells. Int J Cancer 118:571–576PubMedGoogle Scholar
  47. 47.
    Park HS, Cho HY, Ha YL et al. (2004) Dietary conjugated linoleic acid increases the mRNA ratio of Bax/Bcl-2 in the colonic mucosa of rats. J Nutr Biochem 15:229–235PubMedGoogle Scholar
  48. 48.
    Larsson SC, Bergkvist L, Wolk A (2005) High-fat dairy food and conjugated linoleic acid intakes in relation to colorectal cancer incidence in the Swedish Mammography Cohort. Am J Clin Nutr 82:894–900PubMedGoogle Scholar
  49. 49.
    Visonneau S, Cesano A, Tepper SA et al. (1997) Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. Anticancer Res 17:969–973PubMedGoogle Scholar
  50. 50.
    Durgam VR, Fernandes G (1997) The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. Cancer Lett 116:121–130PubMedGoogle Scholar
  51. 51.
    Scimeca JA (1998) Toxicological evaluation of dietary conjugated linoleic acid in male Fischer 344 rats. Food Chem Toxicol 36:391–395PubMedGoogle Scholar
  52. 52.
    Newmark HL (1997) Squalene, olive oil, and cancer risk: a review and hypothesis. Cancer Epidemiol Biomarkers Prev 6:1101–1103PubMedGoogle Scholar
  53. 53.
    Owen RW, Mier W, Giacosa A et al. (2000) Phenolic compounds and squalene in olive oils: the concentration and antioxidant potential of total phenols, simple phenols, secoiridoids, lignans and squalene. Food Chem Toxicol 38:647–659PubMedGoogle Scholar
  54. 54.
    Menendez JA, Vellon L, Colomer R et al. (2005) Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol 16:359–371PubMedGoogle Scholar
  55. 55.
    Alonso L, Fontecha J, Lozada L et al. (1999) Fatty acid composition of caprine milk: major, branched-chain, and trans fatty acids. J Dairy Sci 82:878–884PubMedGoogle Scholar
  56. 56.
    Zapolska-Downar D, Kosmider A, Naruszewicz M (2005) Trans fatty acids induce apoptosis in human endothelial cells. J Physiol Pharmacol 56:611–625PubMedGoogle Scholar
  57. 57.
    Miettinen TA, Vanhanen H (1994) Serum concentration and metabolism of cholesterol during rapeseed oil and squalene feeding. Am J Clin Nutr 59:356–363PubMedGoogle Scholar
  58. 58.
    Strandberg TE, Tilvis RS, Miettinen TA (1990) Metabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatment. J Lipid Res 31:1637–1643PubMedGoogle Scholar
  59. 59.
    Kamimura H, Koga N, Oguri K et al. (1989) Studies on distribution, excretion and subacute toxicity of squalene in dogs. Fukuoka Igaku Zasshi 80:269–280PubMedGoogle Scholar
  60. 60.
    Kelly GS (1999) Squalene and its potential clinical uses. Altern Med Rev 4:29–36PubMedGoogle Scholar
  61. 61.
    Desai KN, Wei H, Lamartiniere CA (1996) The preventive and therapeutic potential of the squalene-containing compound, Roidex, on tumor promotion and regression. Cancer Lett 101:93–96PubMedGoogle Scholar
  62. 62.
    Rao CV, Newmark HL, Reddy BS (1998) Chemopreventive effect of squalene on colon cancer. Carcinogenesis 19:287–290PubMedGoogle Scholar
  63. 63.
    Katdare M, Singhal H, Newmark H et al. (1997) Prevention of mammary preneoplastic transformation by naturally-occurring tumor inhibitors. Cancer Lett 111:141–147PubMedGoogle Scholar
  64. 64.
    Ohkuma T, Otagiri K, Tanaka S et al. (1983) Intensification of host’s immunity by squalene in sarcoma 180 bearing ICR mice. J Pharmacobiodyn 6:148–151PubMedGoogle Scholar
  65. 65.
    Yamaguchi T, Nakagawa M, Hidaka K et al. (1985) Potentiation by squalene of anti-tumor effect of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-nitrosourea in a murine tumor system. Jpn J Cancer Res 76:1021–1026PubMedGoogle Scholar
  66. 66.
    Blaheta RA, Cinatl J Jr. (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22:492–511PubMedGoogle Scholar
  67. 67.
    Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31–59PubMedGoogle Scholar
  68. 68.
    Bjerkedal T, Czeizel A, Goujard J et al. (1982) Valproic acid and spina bifida. Lancet 2:1096PubMedGoogle Scholar
  69. 69.
    Regan CM (1985) Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res 347:394–398PubMedGoogle Scholar
  70. 70.
    Bacon CL, Gallagher HC, Haughey JC et al. (2002) Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem 83:12–19PubMedGoogle Scholar
  71. 71.
    Walmod PS, Skladchikova G, Kawa A et al. (1999) Antiepileptic teratogen valproic acid (VPA) modulates organization and dynamics of the actin cytoskeleton. Cell Motil Cytoskeleton 42:241–255PubMedGoogle Scholar
  72. 72.
    Michaelis M, Michaelis UR, Fleming IT et al. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65:520–527PubMedGoogle Scholar
  73. 73.
    Phiel CJ, Zhang F, Huang EY et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276:36734–36741PubMedGoogle Scholar
  74. 74.
    Cinatl JJr., Kotchetkov R, Blaheta R et al. (2002) Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 20:97–106PubMedGoogle Scholar
  75. 75.
    Blaheta RA, Nau H, Michaelis M et al. (2002) Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 9:1417–1433PubMedGoogle Scholar
  76. 76.
    Cinatl J Jr., Cinatl J, Driever PH et al. (1997) Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8:958–963PubMedGoogle Scholar
  77. 77.
    Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110:943–1954PubMedGoogle Scholar
  78. 78.
    Bergman EN (1990) Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 70:567–590PubMedGoogle Scholar
  79. 79.
    Leder A, Leder P (1975) Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5:319–322PubMedGoogle Scholar
  80. 80.
    Novogrodsky A, Dvir A, Ravid A et al. (1983) Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer (Phila.) 51: 9–14PubMedGoogle Scholar
  81. 81.
    Pouillart P, Cerutti I, Ronco G et al. (1991) Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. Int J Cancer 49:89–95PubMedGoogle Scholar
  82. 82.
    Rephaeli A, Blank-Porat D, Tarasenko N et al. (2005) In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer 116:226–235PubMedGoogle Scholar
  83. 83.
    Nudelman A, Gnizi E, Katz Y et al. (2001) Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur J Med Chem 36:63–74PubMedGoogle Scholar
  84. 84.
    Chen Z-X, Breitman TR (1994) Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 54:3494–3499PubMedGoogle Scholar
  85. 85.
    Giermasz A, Nowis D, Jalili A et al. (2001) Antitumor activity of tributyrin in murine melanoma model. Cancer Lett 164:143–148PubMedGoogle Scholar
  86. 86.
    Yan J, Xu Y-H (2003) Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest. World J Gastroenterol 9:660–664PubMedGoogle Scholar
  87. 87.
    Sartorelli AC, Hodnick WF, Belcourt MF et al. (1994) Mitomycin C: a prototype bioreductive agent. Oncol Res 6:501–508PubMedGoogle Scholar
  88. 88.
    Workman P (1994) Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinine anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6:461–475PubMedGoogle Scholar
  89. 89.
    Ekins S, Kim RB, Leake BF et al. (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974–981PubMedGoogle Scholar
  90. 90.
    Gontero P, Sargent JM, Hopster DJ et al. (2002) Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P-glycoprotein and apoptotic factors. Anticancer Res 22:4073–4080PubMedGoogle Scholar
  91. 91.
    Verweij J, Pinedo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1:5–13PubMedGoogle Scholar
  92. 92.
    Zalipsky S, Gabizon AA (2002) Conjugate having a cleavable linkage for use in a liposome. United States Patent US 6,365,179 B1Google Scholar
  93. 93.
    Senter PD, Pearce WE, Greenfield RS (1990) Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J Org Chem 55:2975–2978Google Scholar
  94. 94.
    Gabizon AA, Tzemach D, Horowitz AT et al. (2006) Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Clin Cancer Res 12:1913–1920PubMedGoogle Scholar
  95. 95.
    Shikano M, Onimura K, Fukai Y et al. (1998)1a-Docosahexaenoyl Mitomycin C: a novel inhibitor of protein tyrosine kinase. Biochem Biophys Res Comm 248:858–863PubMedGoogle Scholar
  96. 96.
    Fornari FA, Randolph JK, Yalowich, JC et al. (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45:649–656PubMedGoogle Scholar
  97. 97.
    Momparler RL, Karon, M, Siegel SE et al. (1976) Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Res 36:2891–2895PubMedGoogle Scholar
  98. 98.
    Di Marco A, Zunino, F, Silvestrini R et al. (1971) Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity. Biochem Pharmacol 20:1323–1328PubMedGoogle Scholar
  99. 99.
    Wang Y, Li L, Jiang W et al. (2006) Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate. Bioorg Med Chem Lett 16:2974–2977PubMedGoogle Scholar
  100. 100.
    Pignatello R, Spampinato G, Sorrenti V et al. (2000) Lipophilic methotrexate conjugates with antitumor activity. Eur J Pharm Sci 10:237–245PubMedGoogle Scholar
  101. 101.
    Goldman ID, Matherly LH (1985) The cellular pharmacology of methotrexate. Pharm Ther 28:77–102Google Scholar
  102. 102.
    Niethammer D, Jackson RC (1975) Changes in the molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11:845–854PubMedGoogle Scholar
  103. 103.
    Kinsky SC, Loader JE (1987) Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives: effect of fatty acid chain length. Biochem Biophys Acta 921:96–103PubMedGoogle Scholar
  104. 104.
    Westerhof GR, Schornagel, JH, Kathmann I et al. (1995) Carrier and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes, correlates of molecular-structure and biological activity. Mol Pharmacol 48:459–471PubMedGoogle Scholar
  105. 105.
    Rosowsky A (1973) Methotrexate analogs. 2. A facile method of preparation of lipophilic derivatives of methotrexate and 3',5'-dichloromethotrexate by direct esterification. J Med Chem 16:1190–1193PubMedGoogle Scholar
  106. 106.
    Chaykovsky M, Rosowsky A, Papathanasopoulos N et al. (1974) Methotrexate analogs. 3. Synthesis and biological properties of some side-chain altered analogs. J Med Chem 17:1212–1216PubMedGoogle Scholar
  107. 107.
    Rosowsky A, Ensminger WD, Lazarus H et al. (1977) Methotrexate analogues. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs. J Med Chem 20:925–930PubMedGoogle Scholar
  108. 108.
    Rosowsky A, Peter Beardsley G, Ensminger WD, et al. (1978) Methotrexate analogues. 11. unambiguous chemical synthesis and in vitro biological evaluation of α- and γ-monoesters as potential prodrugs J Med Chem 21:380–386PubMedGoogle Scholar
  109. 109.
    Rosowsky A, Forsch RA, Yu C-S et al. (1984) Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem 27:605–609PubMedGoogle Scholar
  110. 110.
    Toth I (1994) A novel chemical approach to drug delivery: lipidic amino acid conjugates. J Drug Target 2:217–239PubMedGoogle Scholar
  111. 111.
    Pignatello R, Sorrenti V, Spampinato G et al. (1996) Synthesis and preliminary in vitro screening of lipophilic R,ç-bis (amides) as potential prodrugs of methotrexate. Anti-Cancer Drug Des 14:253–264Google Scholar
  112. 112.
    Pignatello R, Jansen G, Kathmann I et al. (1998) Lipoamino acid conjugates of methotrexate with antitumor activity. J Pharm Sci 87:367–371PubMedGoogle Scholar
  113. 113.
    Pignatello R, Guccione S, Forte S et al. (2004) Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem 12:2951–2964PubMedGoogle Scholar
  114. 114.
    Clarkson BD (1972) Acute myelocytic leukemia in adults. Cancer 30:1572–1582PubMedGoogle Scholar
  115. 115.
    Early AP, Preisler HD, Slocum H (1982) A pilot study of high dose 1-β-D- arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 42:1587–1594PubMedGoogle Scholar
  116. 116.
    Kantarjian H et al. (1983) High-dose cytosine arabinoside in non-Hodgkin’s lymphoma. J Clin Oncol 1:689–694PubMedGoogle Scholar
  117. 117.
    Frei E III, Bickers JN, Hewlett JS et al. (1969) Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res 29:1325–1332PubMedGoogle Scholar
  118. 118.
    Cullinan SA O’Connell MJ, Moertel CG et al. (1977) Phase II study of cytosine arabinoside in advanced large bowel cancer. Cancer Treat Rep 61:1725–1726PubMedGoogle Scholar
  119. 119.
    Ribera JM, Oroil A (2007) A step forward in therapy for ALL in infants. Lancet 370:198–200PubMedGoogle Scholar
  120. 120.
    Roboz GJ (2007) Treatment of acute myeloid leukemia in older patients. Exp Rev Anticancer Ther 7:285–295Google Scholar
  121. 121.
    Angiolillo AL, Whitlock J, Chen MS et al. (2006) Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A children’s oncology group report. Pediatr Blood Cancer 46: 193–197PubMedGoogle Scholar
  122. 122.
    Wagner-Bohn A, Henze G, von Stackelberg A et al. (2006) Phase II study of gemcitabine in children with relapsed leukemia. Pediatr Blood Cancer 46:262–262PubMedGoogle Scholar
  123. 123.
    Heinemann V, Hertel LW, Grindey GB et al. (1988) Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031PubMedGoogle Scholar
  124. 124.
    Bouffard DY, Laliberte J, Momparler RL (1993) Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biocheml Pharmacol 45:1857–1861Google Scholar
  125. 125.
    Ross DD, Cuddy DP (1994) Molecular effects of 2',2'-difluorodeoxycytidine (gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48:1619–1630PubMedGoogle Scholar
  126. 126.
    Huang P, Chubb S, Hertel LW et al. (1991) Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117PubMedGoogle Scholar
  127. 127.
    Chun HG, Leyland-Jones B, Cheson BD (1991) Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 9: 175–188PubMedGoogle Scholar
  128. 128.
    Grove KL, Guo X, Liu SH et al. (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 55:3008–3011PubMedGoogle Scholar
  129. 129.
    Camiener GW, Smith CG (1965) Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmcol 14: 1405–1416Google Scholar
  130. 130.
    Abbruzzese JL, Grunewald R, Weeks EA et al. (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 3:491–498Google Scholar
  131. 131.
    Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875–890PubMedGoogle Scholar
  132. 132.
    Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 327:1056–1061PubMedGoogle Scholar
  133. 133.
    Brachwitz H, Bergmann J, Thomas Y et al. (1999) Synthesis and antiproliferative potency of 9-β-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts. Bioorg Med Chem 7:1195–1200PubMedGoogle Scholar
  134. 134.
    Adema AD, Radi M, Daft J et al. (2007) Troxacitabine prodrugs for pancreatic cancer. Nucleos Nucleot Nucl acids 26:1073–1077Google Scholar
  135. 135.
    Wechter WJ, Johnson MA, Hall CM et al. (1975) Ara-Cytidine acylates. Use of drug design predictors in structure-activity relationship correlation. J Med Chem 18:339–344PubMedGoogle Scholar
  136. 136.
    Neil GL, Wiley PF, Manak RC et al. (1970) Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5'-adamantoate (NSC 117614) in L1210 leukemic mice. Cancer Res 30:1047–1054PubMedGoogle Scholar
  137. 137.
    Wechter WJ, Gish DT, Greig ME et al. (1976) Nucleic acids. 16. Orally active derivatives of ara-cytidine. J Med Chem 19:1013–1017PubMedGoogle Scholar
  138. 138.
    Neil GL, Buskirk HH, Moxley TE et al. (1971) Biochemical and pharmacologic studies with 1-β-D-arabinofuranosylcytosine 5'-adamantoate (NSC-117614), a depot form of cytarabine. Biochem Pharmacol 20:3295–3308PubMedGoogle Scholar
  139. 139.
    Ho DHW, Neil GL (1977) Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine. Cancer Res 37:1640–1643PubMedGoogle Scholar
  140. 140.
    Aoshima M, Tsukagoshi S, Sakurai Y et al. (1976) Antitumor activities of newly synthesized N4-acyl-1-beta-D-arabinofuranosylcytosine. Cancer Res 36:2726–2732PubMedGoogle Scholar
  141. 141.
    Tsuruo T, Iida H, Tsukagoshi S et al. (1979) Comparison of cytotoxic effect and cellular uptake of 1-beta-D-arabinofuranosylcytosine and its N4-acyl derivatives, using cultured KB cells. Cancer Res 39:1063–1070PubMedGoogle Scholar
  142. 142.
    Horber DH, Schott H, Schwendener RA (1995) Cellular pharmacology of N 4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36:483–492PubMedGoogle Scholar
  143. 143.
    Horber DH, von Ballmoos P, Schott H et al. (1995) Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N 4-hexadecyl-1-beta-D-arabinofuranosylcytosine. Br J Cancer 72:1067–1073PubMedGoogle Scholar
  144. 144.
    Bergman AM, Kuiper CM, Noordhuis P et al. (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 23: 1523–1526PubMedGoogle Scholar
  145. 145.
    Bergman AM, Kuiper CM, Voom DA et al. (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67:503–511PubMedGoogle Scholar
  146. 146.
    Breistol K, Balzarini J, Sandvold ML et al. (1999) Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to Cytarabine in metastatic and s.c. human tumor xenografts models. Cancer Res 59: 2944–2949PubMedGoogle Scholar
  147. 147.
    O‘Brien AM, Vey N, Rizzieri DA et al. (2008) A Phase I study with CP-4055 in patients with hematologic malignancies, 44th American Society of Clinical Oncology Annual Meeting, May30-June 3, Abstract #2532Google Scholar
  148. 148.
    Jordheim LP, Cros E, Gouy MH, et al. (2004) Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res 10:5614–5621.PubMedGoogle Scholar
  149. 149.
    Tobias SC, Borch RF (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1:112–116.PubMedGoogle Scholar
  150. 150.
    Raetz CR, Chu MY, Srivastava S et al. (1977) A phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 196:303–305PubMedGoogle Scholar
  151. 151.
    Hong CI, An SH, Buchheit DJ et al. (1986) Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids. J Med Chem 29:2038–2044PubMedGoogle Scholar
  152. 152.
    Hong CI, Kirisits AJ, Buchheit DJ et al. (1986) 1-beta-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs. Cancer Drug Deliv 3:101–113PubMedGoogle Scholar
  153. 153.
    Hong CI, Kirisits AJ, Nechaev A et al. (1990) Nucleoside conjugates. 11. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine and cytidine conjugates of thioether lipids. J Med Chem 33:1380–1386PubMedGoogle Scholar
  154. 154.
    Brachwitz H, Bergmann J, Fichtner I et al. (1998) 1-beta-D-Arabinofuranosylcytosine-5'-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C. J Lipid Res 39:162–172PubMedGoogle Scholar
  155. 155.
    Alexander RL, Morris-Natschke SL, Ishaq KS et al. (2003) Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside. J Med Chem 46:4205–4208PubMedGoogle Scholar
  156. 156.
    Alexander RL, Kucera GL (2005) Lipid nucleoside conjugates for the treatment of cancer. Curr Pharm Des 11:1079–1089PubMedGoogle Scholar
  157. 157.
    Bergman AM, Kuiper CM, Noordhuis P, et al. (2004) Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and human xenografts. Nucleosides Nucleotides Nucleic Acids 23:1329–1333PubMedGoogle Scholar
  158. 158.
    Aamdal S, Awada A, Evans J et al. (2007) A multicenter phase I study of novel nucleoside analogue, CP-4126, in patients with advanced solid tumours-preliminary results. ECCO 14 The European Cancer Conference, Spain September. Abstract #725Google Scholar
  159. 159.
    Myhren F, Borretzen B, Dalen A et al. (2000) Gemcitabine derivatives. Eur Patent. EP0986570Google Scholar
  160. 160.
    Immordino ML, Brusa P, Rocco F et al. (2004) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release 100:331–346PubMedGoogle Scholar
  161. 161.
    Ali SM, Khan AR, Ahmad MU et al. (2005) Synthesis and biological evaluation of gemcitabine–lipid conjugate (NEO6002). Bioorg Med Chem Lett 15:2571–2574PubMedGoogle Scholar
  162. 162.
    Chen P, Chien P-U, Khan AR et al. (2006) In-vitro and in-vivo anti-cancer activity of a novel gemcitabine–cardiolipin conjugate. Anticancer Drugs 17:53–61PubMedGoogle Scholar
  163. 163.
    Couvreur P, Stella B, Reddy LH et al. (2006) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6:2544–2548PubMedGoogle Scholar
  164. 164.
    Couvreur P, Reddy LH, Mangenot S et al. (2008). Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small 4:247–253PubMedGoogle Scholar
  165. 165.
    Reddy LH, Dubernet C, Mouelhi SL et al. (2007) A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 124:20–27PubMedGoogle Scholar
  166. 166.
    Reddy LH, Khoury H, Paci A et al. (2008) Squalenoylation favourably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos 36:1570–1577PubMedGoogle Scholar
  167. 167.
    Reddy LH, Marque PE, Dubernet C et al. (2008) Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther 325:484–490PubMedGoogle Scholar
  168. 168.
    Reddy LH, Ferreira H, Dubernet C et al. (2008) Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anti-Cancer Drugs 19:999–1006PubMedGoogle Scholar
  169. 169.
    Wu W, Sigmond J, Peters GJ et al. (2007) Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem 50:3743–3746PubMedGoogle Scholar
  170. 170.
    Alexander RL, Greene BT, Torti SV, et al. (2005) A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer Chemother Pharmacol 56:15–21PubMedGoogle Scholar
  171. 171.
    Alexander RL, Kucera GL (2005) Lipid nucleoside conjugates for the treatment of cancer. Curr Pharm Des 11:1079–1089PubMedGoogle Scholar
  172. 172.
    Miller ML, Ojima I (2001) Chemistry and chemical biology of taxane anticancer agents. Chem Rec 1:195–211PubMedGoogle Scholar
  173. 173.
    Horwitz SB (1994) Taxol (paclitaxel): mechanisms of action. Ann Oncol 5(6):S3–S6PubMedGoogle Scholar
  174. 174.
    Rowinsky EK (1997) Paclitaxel pharmacology and other tumor types. Semin Oncol 24:S19-1–S19-12PubMedGoogle Scholar
  175. 175.
    Weiss RB, Donehower RC, Wiernik PH et al. (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268PubMedGoogle Scholar
  176. 176.
    Wiernik PH, Schwartz EL, Strauman JJ et al. (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486–2493PubMedGoogle Scholar
  177. 177.
    van Tellingen O, Huizing MT, Panday VR (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335PubMedGoogle Scholar
  178. 178.
    Sparreboom A, van Zuylen L, Brouwer E (1999) Cremophor-EL mediated alteration of paclitaxel distribution in human blood.: clinical pharmacokinetic implications. Cancer Res 59:1454–1457PubMedGoogle Scholar
  179. 179.
    Bernstein B (2000) Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions. Ann Pharmacother 34:1332–1335PubMedGoogle Scholar
  180. 180.
    Casazza AM, Fairchild CR (1996) Paclitaxel (Taxol): mechanisms of resistance. Cancer Treat Res 87:149–171PubMedGoogle Scholar
  181. 181.
    Sparreboom AJ, van Asperen U, Mayer AH et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035PubMedGoogle Scholar
  182. 182.
    Cabral F, Brady RC, Schibler MJ (1986) A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci 466:745–756PubMedGoogle Scholar
  183. 183.
    Cabral F, Barlow SB (1989) Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3:1593–1599PubMedGoogle Scholar
  184. 184.
    Giannakakou P, Sackett DL, Kang, Y-K et al. (1997) Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125PubMedGoogle Scholar
  185. 185.
    Ceruti M, Crosasso P, Brusa P et al. (2000) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing water-soluble prodrugs of paclitaxel. J Control Release 63:141–153PubMedGoogle Scholar
  186. 186.
    Ojima I, Duclos O, Kuduk SD et al. (1994) Synthesis and Biological Activity of 3'-Alkyl- and 3'-Alkenyl-3'-Dephenyldocetaxels. Bioorg Med Chem Lett 4:2631–2634Google Scholar
  187. 187.
    ter Haar E (1998) Taxanes and other microtubule stabilizing agents. Exp Opin Ther Patents 8:571–586Google Scholar
  188. 188.
    Lin S, Ojima I (2000) Recent strategies in the development of taxane anticancer drugs. Exp Opin Ther Patents 10:869–889Google Scholar
  189. 189.
    Ojima I, Slater JC, Michaud E et al. (1996) Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. J Med Chem 39:3889–3896PubMedGoogle Scholar
  190. 190.
    Bradley MO, Webb NL, Anthony FH et al. (2001) Tumor targeting by covalent conjugation of a natural fatty acid to Paclitaxel. Clin Cancer Res 7:3229–3238PubMedGoogle Scholar
  191. 191.
    Henningsson A, Karlsson MO, Vigano L et al. (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19:4065–4073PubMedGoogle Scholar
  192. 192.
    Bradley MO, Swindell CS, Anthony FH et al. (2001) Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 74:233–236PubMedGoogle Scholar
  193. 193.
    Payne M, Ellis P, Dunlop D (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial. J Thorac Oncol 1:984–990PubMedGoogle Scholar
  194. 194.
    Jones RJ, Hawkins RE, Eatock MM et al. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother Pharmacol 61:435–441PubMedGoogle Scholar
  195. 195.
    Mayhew E, Franklin JC, Bhatia S et al. (1996) Hydrophobic taxane derivatives. US patent 5580899Google Scholar
  196. 196.
    Mayhew E, Ali S, Janoff AS (1997) Hydrophobic taxane derivatives. US patent 5703117Google Scholar
  197. 197.
    Lundberg BB, Risovic V, Ramaswamy M et al. (2003) A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 86:93–100PubMedGoogle Scholar
  198. 198.
    Rodrigues DG, Maria DA, Fernandes DC et al. (2005) Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol 55:565–576PubMedGoogle Scholar
  199. 199.
    Nikanjam M, Gibbs AR, Hunt CA et al. (2007) Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 124:163–171PubMedGoogle Scholar
  200. 200.
    Dias ML et al. (2007) Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother Pharmacol 59:105–111PubMedGoogle Scholar
  201. 201.
    Pires LA, Hegg R, Valduga CJ et al. (2008) Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol Mar 26: DOI 10.1007/s00280-008-0738-2Google Scholar
  202. 202.
    Stevens PJ, Sekido M, Lee RJ (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 21:2153–2157PubMedGoogle Scholar
  203. 203.
    Altstadt TJ, Fairchild CR, Golik J, et al. (2001) Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. J Med Chem 44:4577–4583PubMedGoogle Scholar
  204. 204.
    Tarrant JG, Cook D, Fairchild C et al. (2004) Synthesis and biological activity of macrocyclic taxane analogues. Bioorg Med Chem Lett 14:2555–2558PubMedGoogle Scholar
  205. 205.
    Kuznetsova L, Chen J, Sun L et al. (2006) Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg Med Chem Lett 16:974–977PubMedGoogle Scholar
  206. 206.
    Ojima I, Duclos O, Kuduk SD (1994) Synthesis and biological activity of 3ʹ-alkyl- and 3ʹ-alkenyl-3ʹ-dephenyldocetaxels. Bioorg Med Chem Lett 4:2631–2634Google Scholar
  207. 207.
    Ojima I, Fenoglio I, Park YH (1994) Synthesis and biological activity of 14-hydroxydocetaxel. Bioorg Med Chem Lett 4:1571–1576Google Scholar
  208. 208.
    Fite A, Goua M, Wahle KWJ et al. (2007) Potentiation of the anti-tumour effect of docetaxel by conjugated linoleic acids (CLAs) in breast cancer cells in vitro. Prostaglandins Leukot Essent Fatty Acids 77:87–96PubMedGoogle Scholar
  209. 209.
    Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–661PubMedGoogle Scholar
  210. 210.
    Gottlieb JA, Guarino AM, Call JB et al. (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461–470PubMedGoogle Scholar
  211. 211.
    Tsao YP, Russo A, Nyamuswa G et al. (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53:5908–5914PubMedGoogle Scholar
  212. 212.
    Muggia FM, Creven PJ, Jansen HH et al. (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515–521PubMedGoogle Scholar
  213. 213.
    Takayama H, Watanabe A, Hosokawa M, et al. (1998) Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases. Bioorg Med Chem Lett 8:415–418PubMedGoogle Scholar
  214. 214.
    Wang Y, Li L, Jiang W et al. (2005) Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg Med Chem 13:5592–5599PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Faculté de PharmacieUniversité de Paris-Sud XIChâtenay-Malabry CedexFrance
  2. 2.Sanofi-aventisVitry-sur-seineFrance

Personalised recommendations